Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ATRS Hot Sheet
Price: $5.59 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 14
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 6 | New: 14
Join SI Premium – FREE
Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).
For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.
Shares of Antares Pharma closed at $5.58 yesterday.
You May Also Be Interested In
- Tyler Tech (TYL) PT Raised to $500 at Needham
- Kingspan Group PLC (KSP:ID) PT Raised to EUR109 at Goldman Sachs
- Volvo AB (VOLVB:SS) (VLVLY) PT Lowered to SEK350 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
